Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
By Qi Liu, Bernie Sweeney, Marc Feary GS Effex®, derived from Lonza’s leading GS Xceed® cell line, produces molecules that are 100% free of fucose and demonstrate increased potency, without compromising on the titers, growth, stability and product quality that GS Xceed® is known for. Lonza's GS Gene Expression System® is widely used for the expression and manufacturing of biologics.
The pharmaceutical industry is increasingly focused on the development of next-generation drug products that allow the targeted delivery of active ingredients with multiple functionalities, increasing both efficacy and safety. Bi- and multispecific antibodies are prime examples of new drug substances with the potential to offer higher potency combined with new mechanisms of action while also reducing the cost and time for drug development.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
